94 related articles for article (PubMed ID: 29859786)
21. The feasibility of [
Laasik M; Hynninen J; Forsback S; Noponen T; Seppänen M; Hietanen S
EJNMMI Res; 2020 Sep; 10(1):103. PubMed ID: 32910291
[TBL] [Abstract][Full Text] [Related]
22. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.
Li S; Shen L
J Cancer; 2020; 11(17):5056-5068. PubMed ID: 32742453
[TBL] [Abstract][Full Text] [Related]
23. Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy.
Watanabe S; Inoue T; Okamoto S; Magota K; Takayanagi A; Sakakibara-Konishi J; Katoh N; Hirata K; Manabe O; Toyonaga T; Kuge Y; Shirato H; Tamaki N; Shiga T
EJNMMI Res; 2019 Dec; 9(1):104. PubMed ID: 31802264
[TBL] [Abstract][Full Text] [Related]
24. Examining correlations of oxygen sensitive MRI (BOLD/TOLD) with [
Zhou H; Chiguru S; Hallac RR; Yang D; Hao G; Peschke P; Mason RP
Am J Nucl Med Mol Imaging; 2019; 9(2):156-167. PubMed ID: 31139498
[TBL] [Abstract][Full Text] [Related]
25. Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early-stage NSCLC patients with SBRT.
Mohindra P; Sawant A; Griffin RJ; Lamichhane N; Vlashi E; Xu-Welliver M; Dominello M; Joiner MC; Burmeister J
J Appl Clin Med Phys; 2019 Mar; 20(3):7-13. PubMed ID: 30793828
[No Abstract] [Full Text] [Related]
26. Preclinical PET tracers for the evaluation of sarcomas: understanding tumor biology.
Sigal IR; Sebro R
Am J Nucl Med Mol Imaging; 2018; 8(6):428-440. PubMed ID: 30697463
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.
Stieb S; Eleftheriou A; Warnock G; Guckenberger M; Riesterer O
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2201-2217. PubMed ID: 30128659
[TBL] [Abstract][Full Text] [Related]
28. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
30. Repeatability of tumour hypoxia imaging using [
Silvoniemi A; Suilamo S; Laitinen T; Forsback S; Löyttyniemi E; Vaittinen S; Saunavaara V; Solin O; Grönroos TJ; Minn H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):161-169. PubMed ID: 29075831
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
32. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
Komar G; Seppänen M; Eskola O; Lindholm P; Grönroos TJ; Forsback S; Sipilä H; Evans SM; Solin O; Minn H
J Nucl Med; 2008 Dec; 49(12):1944-51. PubMed ID: 18997048
[TBL] [Abstract][Full Text] [Related]
33.
Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
[TBL] [Abstract][Full Text] [Related]
34. Insight into Tumor Hypoxia: Radionuclide-based Biomarker as Diagnostic Tools.
Saxena P; Gambhir S; Dixit M
Curr Top Med Chem; 2023; 23(12):1136-1154. PubMed ID: 37190811
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
